1.98
Tenaya Therapeutics Inc stock is traded at $1.98, with a volume of 8.11M.
It is down -5.71% in the last 24 hours and up +65.00% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
See More
Previous Close:
$2.10
Open:
$2.17
24h Volume:
8.11M
Relative Volume:
2.26
Market Cap:
$322.69M
Revenue:
-
Net Income/Loss:
$-111.13M
P/E Ratio:
-1.50
EPS:
-1.32
Net Cash Flow:
$-91.53M
1W Performance:
+15.12%
1M Performance:
+65.00%
6M Performance:
+301.70%
1Y Performance:
+11.86%
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TNYA
Tenaya Therapeutics Inc
|
1.98 | 342.25M | 0 | -111.13M | -91.53M | -1.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-10-24 | Initiated | William Blair | Outperform |
Nov-30-23 | Initiated | Leerink Partners | Outperform |
Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Momentum divergence signals in Tenaya Therapeutics Inc. chartJuly 2025 EndofMonth & Free Growth Oriented Trading Recommendations - newser.com
Intraday pattern recognizer results for Tenaya Therapeutics Inc.Trade Risk Report & AI Enhanced Trade Execution Alerts - newser.com
What Fibonacci levels say about Tenaya Therapeutics Inc. reboundJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
Should you wait for a breakout in Tenaya Therapeutics Inc.July 2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Statistical indicators supporting Tenaya Therapeutics Inc.’s strengthJuly 2025 Sector Moves & Safe Entry Point Alerts - newser.com
What analysts say about Tenaya Therapeutics Inc stockEarnings Call Summaries & Affordable Growth Trading - earlytimes.in
Tenaya Therapeutics (TNYA): Evaluating Valuation After Investor Buzz on MyPEAK-1 and RIDGE-1 Clinical Updates - Yahoo Finance
Real time scanner hits for Tenaya Therapeutics Inc. explainedEarnings Trend Report & Verified Entry Point Signals - newser.com
Tenaya Therapeutics Stock (TNYA) Opinions on CEO Conference Appearances - Quiver Quantitative
When Will Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Become Profitable? - 富途牛牛
What to expect from Tenaya Therapeutics Inc. in the next 30 daysPortfolio Return Report & Low Volatility Stock Suggestions - newser.com
Why Tenaya Therapeutics Inc. stock appeals to analystsDay Trade & AI Powered Market Trend Analysis - newser.com
Tenaya Therapeutics (NASDAQ:TNYA) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - The Manila Times
Fireside chat Oct 14: Tenaya Therapeutics CEO Faraz Ali at H.C. Wainwright; 1x1 meetings Oct 15, replay 30 days - Stock Titan
Can Tenaya Therapeutics’ Leadership Messaging Shape Long-Term Perceptions and Value Creation for TNYA? - Yahoo Finance
Using RSI to spot recovery in Tenaya Therapeutics Inc.Earnings Beat & Accurate Technical Buy Alerts - newser.com
Is now a turning point for Tenaya Therapeutics Inc.July 2025 Update & Trade Opportunity Analysis - newser.com
Does Tenaya Therapeutics Inc. fit your quant trading model2025 Support & Resistance & High Conviction Buy Zone Picks - newser.com
What recovery options are there for Tenaya Therapeutics Inc.Trade Signal Summary & Expert Approved Momentum Trade Ideas - newser.com
Tenaya Therapeutics CEO Faraz Ali to Speak at Upcoming Investor and Industry Conferences in October 2025 - Quiver Quantitative
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences - The Manila Times
Oct 6 & Oct 21: Tenaya Therapeutics CEO Faraz Ali to Present at Investor Conferences — Webcast Archived 30 Days - Stock Titan
Will Strategic Partnerships Propel SP Refractories Limited Higher in YEARExit Strategy Tips & Maximize Returns With Insights - earlytimes.in
How to manage a losing position in Tenaya Therapeutics Inc.Market Trend Report & Weekly Stock Breakout Alerts - newser.com
What sentiment indicators say about Tenaya Therapeutics Inc. stockEarnings Overview Summary & Step-by-Step Swing Trade Plans - newser.com
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Average Target Price from Brokerages - MarketBeat
Is Tenaya Therapeutics Inc. trending in predictive chart modelsPortfolio Growth Summary & Consistent Return Investment Signals - newser.com
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenaya Therapeutics Inc Stock (TNYA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Tingley Whittemore | Chief Medical Officer |
Aug 18 '25 |
Sale |
1.25 |
5,053 |
6,331 |
172,803 |
Ali Faraz | Chief Executive Officer |
Aug 18 '25 |
Sale |
1.25 |
14,533 |
18,210 |
302,792 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):